Endotoxin-Free Biologics

Endotoxin-Free Biologics Services

Cleaner. Safer. Ready for Clinic.

At Mika Biologics, we believe every biologic should start free of unnecessary burden. For microbial expression systems, the greatest burden has always been endotoxins—lipopolysaccharides (LPS) from Gram-negative bacteria such as E. coli that trigger severe immune responses. Traditionally, endotoxins have been treated as a downstream problem: remove them later, with costly and imperfect purification steps.

But what if you could build biologics that were endotoxin-free from the very beginning?

That’s exactly what we do at Mika. With engineered microbial strains, and optimized bioprocessing, we make endotoxin-free biologics not just possible, but practical. This saves time, reduces costs, simplifies regulatory filings, and, most importantly, delivers safer biologics to patients.

We are proud to be the first CDMO to offer endotoxin-free biologics as a dedicated service line—leading not just the U.S. market, not just the world, but the galaxy. (Other universes? We’ll let you know once we’ve audited them.)

Mika Biologics CDMO, bioreactors and scientist in lab suit

Why Endotoxin-Free Biologics Matter

Endotoxins are fragments of bacterial cell walls, specifically LPS molecules embedded in the outer membrane of Gram-negative bacteria. When present in biologics, they can:

  • Trigger immune reactions – pyrogenicity, fever, sepsis-like responses.
  • Complicate QC testing – with frequent assay failures.
  • Drive regulatory risk – FDA and EMA have strict endotoxin limits (e.g., USP <85> LAL assays).
  • Increase costs – endotoxin removal steps are expensive, unpredictable, and often reduce yield.

For many biologics—cytokines, enzymes, plasmids, VLPs—endotoxin risk is not just a nuisance, it is a program-stopper.

Traditional CDMOs view endotoxin removal as a downstream cleanup issue. At Mika Biologics, we take the opposite approach: endotoxin is prevented at the source, through engineered hosts and workflows. This makes the entire process cleaner, safer, and faster.

Our Endotoxin-Free Biologics Services

Mika Biologics offers the world’s first dedicated endotoxin-free CDMO platform, designed to take biologics from R&D through GMP with cleaner, safer processes.

Endotoxin-Free Expression Systems
We engineer microbial strains and workflows that minimize or eliminate lipopolysaccharide (LPS) contamination at the source. By preventing endotoxin formation during expression, our platform delivers biologics that are clinic-ready without the need for excessive downstream clearance.

Capabilities

  • Endotoxin-free plasmid DNA production.
  • Recombinant proteins expressed in low-LPS microbial environments.
  • Enzymes, cytokines, VLPs, and other complex biologics manufactured with reduced risk of endotoxin contamination.

Advantages

  • Prevents endotoxin carryover at the source, reducing or eliminating downstream clearance steps.
  • Simplifies regulatory submissions with cleaner CMC packages.
  • Improves yields by avoiding harsh purification methods that damage product quality.
  • Speeds development timelines while ensuring safer biologics for patients.

2. Custom Endotoxin-Free Strain Development

Not every project fits ClearColi. We engineer bespoke microbial hosts tailored to client needs:

  • Knockout strains for LPS biosynthetic pathways.
  • CRISPR-edited E. coli variants with optimized growth.
  • Endotoxin-reduced yeast and fungal systems.

This ensures flexibility: whether you’re expressing cytokines, CRISPR proteins, or nanoparticle scaffolds, we design hosts that are both productive and endotoxin-safe.

3. Endotoxin-Free Plasmid Manufacturing

Plasmids are the backbone of gene therapy, mRNA vaccines, and engineered probiotics. Endotoxin contamination in plasmids is a regulatory red flag.

Services:

  • ClearColi® plasmid production.
  • GMP-grade purification with low-endotoxin profiles.
  • Large-scale plasmid prep for clinical and commercial use.

By starting with endotoxin-free hosts, we provide plasmids that pass QC on the first try.

4. Endotoxin-Free Protein Biologics

We extend endotoxin-free systems to therapeutic proteins:

  • Cytokines & Immunomodulators – IL-2, GM-CSF, interferons.
  • Enzymes – therapeutic enzymes, polymerases, ligases.
  • VLPs & Nanoparticles – vaccine scaffolds free from endotoxin burden.

Each is validated with activity assays and endotoxin testing, ensuring clinical-grade quality.

5. Downstream Simplification

Even in endotoxin-free systems, we add fail-safe purification:

  • Chromatography tuned for high selectivity.
  • TFF with endotoxin-reduction membranes.
  • Automated LAL and recombinant Factor C assays for release.

By removing the problem at the source, downstream becomes simpler, faster, and cheaper.

Why Choose Mika for Endotoxin-Free Biologics?

Most CDMOs tolerate endotoxins as an inevitable cost. Mika Biologics rejects that premise.

1. Microbial-First, Endotoxin-Free

We lead with microbial hosts that are engineered to be safe from the start.

2. Regulatory Advantage

We build cleaner CMC packages, making filings smoother and more defensible.

3. Cost & Yield Savings

Without harsh endotoxin removal, yields rise and costs fall.

4. GMP-Ready from Day One

Our facilities are validated for endotoxin-free GMP runs.

5. Galaxy-Class Thought Leadership

We are not just a CDMO—we are the first global thought leader in endotoxin-free biologics.

Technical Infrastructure

Our facilities are optimized for endotoxin-free production:

  • Fermentation – 1–2000 L microbial fermentation, with engineered strains.
  • Plasmid Manufacturing Suites – ClearColi®-dedicated lines.
  • Downstream Processing – chromatography, TFF, lyophilization, sterile filtration.
  • Endotoxin Assays – LAL, recombinant Factor C, kinetic turbidimetric assays.
  • Quality Systems – ISO-aligned, FDA-registered, EU-compliant.

Applications & Case Studies

  • Gene Therapy Biotech – partnered with Mika for plasmid supply, reducing endotoxin failures by 90%.
  • Immunotherapy Innovator – IL-2 manufactured endotoxin-free, accelerating IND approval.
  • Diagnostics Provider – endotoxin-free polymerases validated for ultra-sensitive qPCR assays.
  • Vaccine Developer – VLPs manufactured with ClearColi®, eliminating costly clearance steps.

What Are Endotoxins?

  • Lipopolysaccharides (LPS) anchored in Gram-negative membranes.
  • Extremely potent activators of human immune system (via TLR4/MD-2 complex).
  • Can cause pyrogenicity, cytokine storms, or even sepsis-like responses at nanogram levels.

Why They’re Hard to Remove

  • LPS are amphipathic molecules—sticky and resilient.
  • Standard methods (ion exchange, ultrafiltration, Triton X-114) are:
    • Costly
    • Yield-reducing
    • Unreliable

Engineering the Solution

  • ClearColi® removes 7 genes from the LPS biosynthetic pathway.
  • Produces lipid IVa, which is not immunostimulatory in humans.
  • Mika builds on this foundation with next-gen engineered hosts, combining:
    • Higher cell densities.
    • Tuned metabolic flux.
    • Endotoxin-reduced glycosylation.

The Future of Endotoxin-Free Biologics

We see a future where endotoxin-free is the default, not the exception.

  • Next-Gen Hosts – engineered E. coli, yeast, and fungi with minimized pyrogenicity.
  • Portable Endotoxin-Free Systems – freeze-dried plasmid and protein kits, ready for point-of-care.
  • AI-Driven Strain Design – predictive modeling to reduce endotoxin biosynthesis pathways.
  • Global Regulatory Adoption – pushing for recognition of endotoxin-free strains as regulatory gold standards.
  • Cross-Platform Integration – endotoxin-free systems feeding into cell-free extracts, immune biologics, and microbial vaccines.

At Mika, we’re not just making endotoxin-free biologics. We’re building the future standard of biologics manufacturing.

Closing Statement

Endotoxins are the hidden tax of microbial biologics. For decades, they’ve been tolerated as a nuisance to be cleaned up later. At Mika Biologics, we’ve flipped the model: build biologics endotoxin-free from the start, and every step of development becomes cleaner, safer, faster, and more efficient.

We are proud to be the first dedicated endotoxin-free CDMO service line—not just in the U.S., not just globally, but across the galaxy. Our clients don’t waste time fighting LPS—they build therapies that matter.

Mika Biologics. Microbial Systems. Immune Innovation. Beyond the Cell.

Contact our sales team at info@mikabiologics.com